indeed correct Ahjay
pre market - 250 ADRs @ US$4.00
No- one has yet commented on latest Novartis trial Lag 525 combo Avelumab (PD-1 and chemo) in TNBC (late stage - allcommer PD-1) that failed to meet efficacy endpoints and is discontinued.
Great opportunity for 'shorts' to put the scare tactics on US retail 'whits plus end of month closing out positions and impending AIPAC final OS in MBC (PD-1 all comer with chemo).
Perfect storm.
Novartis partnership- best case would be 1-2 % of future revenue/market cap.
Could be well wrong on above. But seen it many times before.....like taking 'candy from a baby' for market makers and sophs who will be happy to soak up shares at current and probably lower levels - if Daq IMMP follows through to ASX IMM tomorrow - end of mon,I'm
ready with plenty of 'ammo' if needs be.
Two weeks to go and 'late breaking abstracts' do not fall out of the proverbial trees....
indeed correct Ahjay pre market - 250 ADRs @ US$4.00 No- one has...
-
- There are more pages in this discussion • 92 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.005(1.64%) |
Mkt cap ! $436.3M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.3¢ | 30.0¢ | $960.6K | 3.161M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 188729 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 46153 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |